Literature DB >> 17686377

The effect of angiotensin receptor blockers for preventing atrial fibrillation.

Kristian Wachtell1, Richard B Devereux, And Paulette A Lyle.   

Abstract

Atrial fibrillation is the most common sustained cardiac arrhythmia in clinical practice, and causes significant burden to patients and health care systems. Clinicians treat existing atrial fibrillation with anticoagulation and/or drugs that utilize either a rate or rhythm control strategy. It remains unclear how best to reduce cardiovascular morbidity and mortality in this population. Prevention of atrial fibrillation using angiotensin receptor blockers, which affect ion currents and refractoriness in atrial myocytes, regress or prevent atrial fibrosis, decrease left atrial size, regress left ventricular hypertrophy, modulate sympathetic nerve activity, reduce inflammation, and reduce blood pressure, may become an important and desirable alternative.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17686377     DOI: 10.1007/s11906-007-0051-1

Source DB:  PubMed          Journal:  Curr Hypertens Rep        ISSN: 1522-6417            Impact factor:   5.369


  49 in total

Review 1.  Should atrial fibrillation ablation be considered first-line therapy for some patients? Why atrial fibrillation ablation should be considered first-line therapy for some patients.

Authors:  Atul Verma; Andrea Natale
Journal:  Circulation       Date:  2005-08-23       Impact factor: 29.690

2.  Atrial contractile dysfunction after short-term atrial fibrillation is reduced by verapamil but increased by BAY K8644.

Authors:  E Leistad; G Aksnes; E Verburg; G Christensen
Journal:  Circulation       Date:  1996-05-01       Impact factor: 29.690

Review 3.  Epidemiology and mechanism of atrial fibrillation and atrial flutter.

Authors:  A J Camm; O A Obel
Journal:  Am J Cardiol       Date:  1996-10-17       Impact factor: 2.778

Review 4.  Vascular and cardiac benefits of angiotensin receptor blockers.

Authors:  Ernesto L Schiffrin
Journal:  Am J Med       Date:  2002-10-01       Impact factor: 4.965

5.  Differential inhibition of the prejunctional actions of angiotensin II in rat atria by valsartan, irbesartan, eprosartan, and losartan.

Authors:  S S Shetty; D DelGrande
Journal:  J Pharmacol Exp Ther       Date:  2000-07       Impact factor: 4.030

6.  Increased expression of extracellular signal-regulated kinase and angiotensin-converting enzyme in human atria during atrial fibrillation.

Authors:  A Goette; T Staack; C Röcken; M Arndt; J C Geller; C Huth; S Ansorge; H U Klein; U Lendeckel
Journal:  J Am Coll Cardiol       Date:  2000-05       Impact factor: 24.094

7.  Regulation of angiotensin II receptor subtypes during atrial fibrillation in humans.

Authors:  A Goette; M Arndt; C Röcken; A Spiess; T Staack; J C Geller; C Huth; S Ansorge; H U Klein; U Lendeckel
Journal:  Circulation       Date:  2000-06-13       Impact factor: 29.690

8.  Cardiovascular morbidity and mortality in hypertensive patients with a history of atrial fibrillation: The Losartan Intervention For End Point Reduction in Hypertension (LIFE) study.

Authors:  Kristian Wachtell; Björn Hornestam; Mika Lehto; David J Slotwiner; Eva Gerdts; Michael H Olsen; Peter Aurup; Björn Dahlöf; Hans Ibsen; Stevo Julius; Sverre E Kjeldsen; Lars H Lindholm; Markku S Nieminen; Jens Rokkedal; Richard B Devereux
Journal:  J Am Coll Cardiol       Date:  2005-03-01       Impact factor: 24.094

9.  Prevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation: population-based estimates.

Authors:  W B Kannel; P A Wolf; E J Benjamin; D Levy
Journal:  Am J Cardiol       Date:  1998-10-16       Impact factor: 2.778

10.  Effect of losartan on sudden cardiac death in people with diabetes: data from the LIFE study.

Authors:  Lars H Lindholm; Björn Dahlöf; Jonathan M Edelman; Hans Ibsen; Knut Borch-Johnsen; Michael Hecht Olsen; Steven Snapinn; Kristian Wachtell
Journal:  Lancet       Date:  2003-08-23       Impact factor: 79.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.